Data-Derived Modeling Characterizes Plasticity of MAPK Signaling in Melanoma

PLoS Computational Biology

Volumn 10, Issue 9, 2014, Pages

  Bernardo Faura, Marti ^a,b,f   Massen, Stefan ^a,c   Falk, Christine S ^c,d   Brady, Nathan R ^a,e   Eils, Roland ^a,b  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d German Center for Infectious Diseases (DZIF) TTU IICH   (Germany)

^e UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^f WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; CELL SIGNALING; DERMATOLOGY; DISEASES; DRUG THERAPY; ENZYMES; NETWORK ARCHITECTURE; ONCOLOGY; SIGNAL TRANSDUCTION; SIGNALING; TOPOLOGY;

CANCER THERAPY; COMPUTATIONAL MODELLING; DYNAMIC NONLINEAR BEHAVIOURS; FUZZY LOGIC MODELING; MAPK SIGNALLING; MODELING APPROACH; NEO-VASCULARIZATION; SIGNAL TRANSDUCTION PATHWAYS; SIGNALLING PATHWAYS; SOMATIC MUTATION;

FUZZY LOGIC;

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ACTIVATING TRANSCRIPTION FACTOR 2; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; ENZYME INHIBITOR; I KAPPA B KINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; SELUMETINIB; SORAFENIB; STRESS ACTIVATED PROTEIN KINASE;

ALTERNATIVE RNA SPLICING; ARTICLE; CANCER CELL LINE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; ENZYME PHOSPHORYLATION; EVOLUTION; FEEDBACK SYSTEM; FUZZY LOGIC; HUMAN; HUMAN CELL; MATHEMATICAL MODEL; MELANOMA; MOLECULAR BIOLOGY; MOLECULAR DYNAMICS; NORMAL DISTRIBUTION; PREDICTION; SENSITIVITY ANALYSIS; SIGNAL TRANSDUCTION; BIOLOGICAL MODEL; BIOLOGY; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY;

COMPUTATIONAL BIOLOGY; FUZZY LOGIC; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOMA; MODELS, BIOLOGICAL; PHOSPHORYLATION;

EID: 84907588582     PISSN: 1553734X     EISSN: 15537358     Source Type: Journal    
DOI: 10.1371/journal.pcbi.1003795     Document Type: Article

References (49)

1. Dumont JE, Pécasse F, Maenhaut C, (2001) Crosstalk and specificity in signalling. Are we crosstalking ourselves into general confusion? Cell Signal 13: 457–463.
2. Di Nicolantonio F, Mercer SJ, Knight LA, Gabriel FG, Whitehouse PA, et al. (2005) Cancer cell adaptation to chemotherapy. BMC Cancer 5: 78 doi:10.1186/1471-2407-5-78
3. Hendrix MJC, Seftor EA, Hess AR, Seftor REB, (2003) Molecular plasticity of human melanoma cells. Oncogene 22: 3070–3075 doi:10.1038/sj.onc.1206447
4. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, et al. (2010) Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18: 683–695 doi:10.1016/j.ccr.2010.11.023
5. Ramgolam K, Lauriol J, Lalou C, Lauden L, Michel L, et al. (2011) Melanoma Spheroids Grown Under Neural Crest Cell Conditions Are Highly Plastic Migratory/Invasive Tumor Cells Endowed with Immunomodulator Function. PLoS ONE 6: e18784 doi:10.1371/journal.pone.0018784.g011
6. Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, et al. (2010) Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF. Cell 140: 209–221 doi:10.1016/j.cell.2009.12.040
7. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417: 949–954 doi:10.1038/nature00766
8. Davies MA, Samuels Y, (2010) Analysis of the genome to personalize therapy for melanoma. Oncogene 29: 5545–5555 doi:10.1038/onc.2010.323
9. Kurada BRV, Li LC, Mulherkar N, Subramanian M, Prasad KV, et al. (2009) MADD, a Splice Variant of IG20, Is Indispensable for MAPK Activation and Protection against Apoptosis upon Tumor Necrosis Factor-α Treatment. Journal of Biological Chemistry 284: 13533–13541.
10. Kholodenko BN, Hancock JF, Kolch W, (2010) Signalling ballet in space and time. Nat Rev Mol Cell Biol 11: 414–426 Available: http://www.nature.com/doifinder/10.1038/nrm2901.
11. Kiel C, Serrano L, (2011) Challenges ahead in signal transduction: MAPK as an example. Current Opinion in Biotechnology 1–10 doi:10.1016/j.copbio.2011.10.004
12. Blüthgen N, Legewie S, (2012) Robustness of signal transduction pathways. Cell Mol Life Sci doi:10.1007/s00018-012-1162-7
13. Ma W, Trusina A, El-Samad H, Lim WA, Tang C, (2009) Defining Network Topologies that Can Achieve Biochemical Adaptation. Cell 138: 760–773 doi:10.1016/j.cell.2009.06.013
14. Spencer SL, Sorger PK, (2011) Measuring and Modeling Apoptosis in Single Cells. Cell 144: 926–939 doi:10.1016/j.cell.2011.03.002
15. Saez-Rodriguez J, Alexopoulos LG, Epperlein J, Samaga R, Lauffenburger DA, et al. (2009) Discrete logic modelling as a means to link protein signalling networks with functional analysis of mammalian signal transduction. Molecular Systems Biology 5: 1–19 doi:10.1038/msb.2009.87
16. Aldridge BB, Saez-Rodriguez J, Muhlich JL, Sorger PK, Lauffenburger DA, (2009) Fuzzy Logic Analysis of Kinase Pathway Crosstalk in TNF/EGF/Insulin-Induced Signaling. PLoS Comput Biol 5: e1000340 doi:10.1371/journal.pcbi.1000340.g007
17. Bosl WJ, (2007) Systems biology by the rules: hybrid intelligent systems for pathway modeling and discovery. BMC Syst Biol 1: 13 doi:10.1186/1752-0509-1-13
18. Huang Z, Hahn J, (2009) Fuzzy modeling of signal transduction networks. Chemical Engineering Science 64: 2044–2056 doi:10.3182/20080706-5-KR-1001.0384
19. Reis Y, Bernardo-Faura M, Richter D, Wolf T, Brors B, et al. (2012) Multi-Parametric Analysis and Modeling of Relationships between Mitochondrial Morphology and Apoptosis. PLoS ONE 7: e28694 doi:10.1371/journal.pone.0028694.t001
20. Morris MK, Saez-Rodriguez J, Clarke DC, Sorger PK, Lauffenburger DA, (2011) Training Signaling Pathway Maps to Biochemical Data with Constrained Fuzzy Logic: Quantitative Analysis of Liver Cell Responses to Inflammatory Stimuli. PLoS Comput Biol 7: e1001099 doi:10.1371/journal.pcbi.1001099.t003
21. Polzien L, Baljuls A, Albrecht M, Hekman M, Rapp UR, (2011) BAD Contributes to RAF-mediated Proliferation and Cooperates with B-RAF-V600E in Cancer Signaling. Journal of Biological Chemistry 286: 17934–17944 doi:10.1074/jbc.M110.177345
22. Terfve C, Saez-Rodriguez J, (2012) Modeling signaling networks using high-throughput phospho-proteomics. Adv Exp Med Biol 736: 19–57 doi:10.1007/978-1-4419-7210-1_2
23. Kholodenko BN, (2000) Negative feedback and ultrasensitivity can bring about oscillations in the mitogen-activated protein kinase cascades. Eur J Biochem 267: 1583–1588.
24. Liu Y, Shepherd EG, Nelin LD, (2007) MAPK phosphatases — regulating the immune response. Nat Rev Immunol 7: 202–212 doi:10.1038/nri2035
25. Zadeh LA, (1968) Probability measures of fuzzy events. Journal of mathematical analysis and applications 23: 421–427.
26. Übeyli ED, (2009) Adaptive neuro-fuzzy inference system for classification of ECG signals using Lyapunov exponents. Computer Methods and Programs in Biomedicine 93: 313–321 doi:10.1016/j.cmpb.2008.10.012
27. Chiu SL, (1994) Fuzzy model identification based on cluster estimation. Journal of intelligent and Fuzzy systems
28. Wang Z, Palade V, (2011) Building interpretable fuzzy models for high dimensional data analysis in cancer diagnosis. BMC Genomics 12: S5 doi:10.1186/1471-2164-12-S2-S5
29. Bulavin DV, Saito S, Hollander MC, Sakaguchi K, Anderson CW, et al. (1999) Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. EMBO J 18: 6845–6854 doi:10.1093/emboj/18.23.6845
30. Fuchs SY, Adler V, Pincus MR, Ronai Z, (1998) MEKK1/JNK signaling stabilizes and activates p53. Proc Natl Acad Sci USA 95: 10541–10546.
31. Jang JSR, (1993) ANFIS: adaptive-network-based fuzzy inference system. IEEE Trans Syst, Man, Cybern 23: 665–685 doi:10.1109/21.256541
32. Takagi T, Sugeno M, (1985) Fuzzy identification of systems and its applications to modeling and control. IEEE Trans Syst, Man, Cybern SMC-15: 116–132 doi:10.1109/TSMC.1985.6313399
33. Efron B, (1979) Bootstrap methods: another look at the jackknife. The Annals of Statistics 7: 1–26.
34. James G, Witten D, Hastie T, Tibshirani R (2013) An Introduction to Statistical Learning. New York, NY: Springer New York. doi:10.1007/978-1-4614-7138-7.
35. Vivanco I, Palaskas N, Tran C, Finn SP, Getz G, et al. (2007) Identification of the JNK Signaling Pathway as a Functional Target of the Tumor Suppressor PTEN. Cancer Cell 11: 555–569 doi:10.1016/j.ccr.2007.04.021
36. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, et al. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Research 64: 7099–7109 doi:10.1158/0008-5472.CAN-04-1443
37. Yeh TC, Marsh V, Bernat BA, Ballard J, Colwell H, et al. (2007) Biological Characterization of ARRY-142886 (AZD6244), a Potent, Highly Selective Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitor. Clinical Cancer Research 13: 1576–1583 doi:10.1158/1078-0432.CCR-06-1150
38. Davies BR, Logie A, McKay JS, Martin P, Steele S, et al. (2007) AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 6: 2209–2219 doi:10.1158/1535-7163.MCT-07-0231
39. Roberts PJ, Der CJ, (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26: 3291–3310 doi:10.1038/sj.onc.1210422
40. Fukuda M, Gotoh Y, Nishida E, (1997) Interaction of MAP kinase with MAP kinase kinase: its possible role in the control of nucleocytoplasmic transport of MAP kinase. EMBO J 16: 1901–1908 doi:10.1093/emboj/16.8.1901
41. Panka DJ, (2006) The Raf Inhibitor BAY 43-9006 (Sorafenib) Induces Caspase-Independent Apoptosis in Melanoma Cells. Cancer Research 66: 1611–1619 doi:10.1158/0008-5472.CAN-05-0808
42. Gaudet S, Janes KA, Albeck JG, Pace EA, Lauffenburger DA, et al. (2005) A compendium of signals and responses triggered by prodeath and prosurvival cytokines. Mol Cell Proteomics 4: 1569–1590 doi:10.1074/mcp.M500158-MCP200
43. Vivanco I, Sawyers CL, (2002) The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2: 489–501 doi:10.1038/nrc839
44. Aikin R, (2004) Cross-Talk between Phosphatidylinositol 3-Kinase/AKT and c-Jun NH2-Terminal Kinase Mediates Survival of Isolated Human Islets. Endocrinology 145: 4522–4531 doi:10.1210/en.2004-0488
45. Wynn ML, Consul N, Merajver SD, Schnell S, (2012) Logic-based models in systems biology: a predictive and parameter-free network analysis method. Integr Biol 4: 1323 doi:10.1039/c2ib20193c
46. Morris MK, Saez-Rodriguez J, Sorger PK, Lauffenburger DA, (2010) Logic-Based Models for the Analysis of Cell Signaling Networks. Biochemistry 49: 3216–3224 doi:10.1021/bi902202q
47. Marshall CJ, (1995) Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80: 179–185.
48. Grecco HE, Schmick M, Bastiaens PIH, (2011) Signaling from the living plasma membrane. Cell 144: 897–909 doi:10.1016/j.cell.2011.01.029
49. Mamdani EH, Assilian S, (1999) An experiment in linguistic synthesis with a fuzzy logic controller. International journal of human-computer studies 51: 135–147.